Abstract

We retrospectively enrolled 825 breast cancer patients, who was primarily diagnosed in our hospital between January 2009 and December 2014 and explored the relationship between red blood cell distribution width (RDW) and long-term prognosis in patients with breast cancer. There were 412 patients with high RDW (RDW > 13.82) and 413 patients with low RDW (RDW ≤ 13.82). Compared with low RDW group, the high w group has large tumor size (the rate of tumor size >2 cm: 60.7 vs 44.8%, P=0.013). The rate of lymph node metastases was higher in the high RDW group thaten that in the low RDW group (62.1 vs 45.8%, P=0.000). RDW was positively associated with tumor stage. The high RDW tended to be advanced stage (P=0.000). Compared with low RDW group, the high RDW group tended to be higher lymphocyte count (P=0.004), elevated fibrinogen (P=0.043), and elevated high-sensitivity C-reactive protein (P=0.000). The Kaplan–Meier analysis indicated elevated RDW was positively associated with disease-free survival (DFS) (P=0.004) and overall survival (OS) (P=0.011). The multivariate Cox regression analysis indicated that the high RDW group had poorer OS (Hazard risk [HR] = 2.43; 95% CI: 1.62–3.21; P=0.024) and DFS (HR = 1.89; 95% CI: 1.28–3.62; P=0.000) compared with low RDW group. The present study found that high pretreatment RDW levels in breast cancer patients were associated with poor OS and DFS. RDW could be a potential predictive factor in differential diagnosis of poor prognosis from all patients.

Highlights

  • Breast cancer is one of the most common female malignancies worldwide and with a heavy mortality [1]

  • The present study suggested that elevated preoperative red blood cell distribution width (RDW) was associated with poor prognosis in patients with breast cancer and was an independent predictor of poor survival in women with breast cancer

  • Our results indicated that we should pay more attention on these patients who have higher preoperational RDW

Read more

Summary

Introduction

Breast cancer is one of the most common female malignancies worldwide and with a heavy mortality [1]. The morbidity of breast cancer is prone to be leading female malignancies in China [2]. Comprehensive treatment based on surgical treatment has significantly improved the prognosis of breast cancer patients, its overall prognosis is still not ideal [4,5]. Based on these concepts, breast cancer should be considered as a systemic disease and some molecular biomarkers should be needed in precision medicine for breast cancer. It is of great significance to seek a simple, convenient, and sensitive prognostic indicator of breast cancer for early detection of tumors and guidance of treatment decisions

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call